Study Name Principal Investigator
(ACCUTE) Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study of AB103 as Compared to Placebo in Patients with Necrotizing Soft Tissue Infections (NSTI) ACCUTE (AB103 Clinical Composite Endpoint Study in Necrotizing Soft Tissue Infections) Young, Lester
A Phase 3, randomized, placebo-controlled, double-blind clinical study of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) to evaluate the safety and efficacy of pembrolizumab and lenvatinib as 1L intervention in a PD-L1 selected population of participants with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) (LEAP-010). Guddati, Achuta
ADXS001-04: Phase 1-2 Study of MEDI4736 Alone or In Combination with ADXS11-001 In Recurrent/Persistent or Metastatic Cervical or HPV+ Head & Neck Cancer Ghamande, Sharad
C-145-04: A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic or Persistent Cervical Carcinoma Ghamande, Sharad
Developmental Gene Discovery Project: Mapping and Identifying New Genes in Uterine and Vaginal Development; Identifying New Genes Causing Birth Defects in Children Layman, Lawrence
GENETIC TESTING IN AFRICAN AMERICANS Towards Universal Paired Tumor/Germline Genetic Testing in Solid Tumor Patients with Specific Gynecological Malignancies Henson, John
Georgetown STUDY00003849: A phase II trial of combination therapy of pembrolizumab and lenvatinib in patients with locally advanced or metastatic cervical cancer Ghamande, Sharad
TESARO 4010-01-001: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors Ghamande, Sharad
RESEARCH. INNOVATION. DISCOVERY.
Augusta University
Research
AU Health
Stay Informed
Get updates on new trials and more
(706)721-6582 © Augusta University 1120 15th Street Augusta, GA 30912